Biocon rose 1.04% to Rs 413.90 after the company s subsidiary signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia.Biocon Biologics, a fully integrated pure play biosimilars company and a subsidiary of Biocon, has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asiaas a part of the Cancer Access Partnership (CAP).
The partnership is a significant step in delivering advanced cancer therapies to patientswho need them the most and ensuring equitable access to high-quality biosimilars in low-and middle-income countries (LMICs).